EP1143990A3 - Pharmazeutische zusammensetzung, enthaltend peg-asparaginase, für die behandlung von hiv infektionen - Google Patents

Pharmazeutische zusammensetzung, enthaltend peg-asparaginase, für die behandlung von hiv infektionen

Info

Publication number
EP1143990A3
EP1143990A3 EP00957306A EP00957306A EP1143990A3 EP 1143990 A3 EP1143990 A3 EP 1143990A3 EP 00957306 A EP00957306 A EP 00957306A EP 00957306 A EP00957306 A EP 00957306A EP 1143990 A3 EP1143990 A3 EP 1143990A3
Authority
EP
European Patent Office
Prior art keywords
asparaginase
peg
treatment
hiv infections
pharmaceutical compostions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00957306A
Other languages
English (en)
French (fr)
Other versions
EP1143990A2 (de
Inventor
Vassilios L. Avramis
Lewis Cohen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enzon Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/370,390 external-priority patent/US6689762B1/en
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Publication of EP1143990A2 publication Critical patent/EP1143990A2/de
Publication of EP1143990A3 publication Critical patent/EP1143990A3/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP00957306A 1999-08-06 2000-08-07 Pharmazeutische zusammensetzung, enthaltend peg-asparaginase, für die behandlung von hiv infektionen Withdrawn EP1143990A3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US370390 1982-04-21
US09/370,390 US6689762B1 (en) 1998-02-09 1999-08-06 Composition and methods for treatment of HIV infection
PCT/US2000/021462 WO2001010454A2 (en) 1999-08-06 2000-08-07 Pharmaceutical composition comprising peg-asparaginase for the treatment of hiv infection

Publications (2)

Publication Number Publication Date
EP1143990A2 EP1143990A2 (de) 2001-10-17
EP1143990A3 true EP1143990A3 (de) 2002-03-27

Family

ID=23459436

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00957306A Withdrawn EP1143990A3 (de) 1999-08-06 2000-08-07 Pharmazeutische zusammensetzung, enthaltend peg-asparaginase, für die behandlung von hiv infektionen

Country Status (7)

Country Link
EP (1) EP1143990A3 (de)
JP (1) JP2003506409A (de)
AU (1) AU6894400A (de)
CA (1) CA2346063A1 (de)
HK (1) HK1041444A1 (de)
WO (1) WO2001010454A2 (de)
ZA (1) ZA200102506B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085358A2 (en) * 2001-04-20 2002-10-31 Vion Pharmaceuticals, Inc. Antiviral agents and methods of treating viral infections
US8029815B2 (en) 2004-04-28 2011-10-04 Elford Howard L Methods for treating or preventing restenosis and other vascular proliferative disorders
EP2030615A3 (de) 2007-08-13 2009-12-02 ELFORD, Howard L. Ribonukleotidreduktase-Inhibitoren zur Verwendung für die Behandlung oder Vorbeugung von Nervenentzündung- oder Autoimmunerkrankungen
US9556216B2 (en) 2012-08-31 2017-01-31 Novartis Ag 2′-Ethynyl nucleoside derivatives for treatment of viral infections
BR112018074646A2 (pt) * 2016-05-31 2019-03-06 Taiho Pharmaceutical Co., Ltd. composto de sulfonamida ou sal do mesmo
US10889555B2 (en) 2016-05-31 2021-01-12 Taiho Pharmaceutical Co., Ltd. Sulfonamide compound or salt thereof
CA3084030C (en) * 2017-11-29 2023-03-21 Taiho Pharmaceutical Co., Ltd. Sulfonamide compounds and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2600256B1 (fr) * 1986-06-19 1988-09-16 Inst Nat Sante Rech Med Medicament et composition medicamenteuse pour le traitement des tumeurs ainsi que pour le traitement des maladies infectieuses dues aux virus
WO1998056410A1 (en) * 1997-06-09 1998-12-17 Childrens Hospital Los Angeles Utilization of wolinella succinogenes asparaginase to treat diseases associated with asparagine dependence
ES2203072T3 (es) * 1998-02-09 2004-04-01 Enzon Pharmaceuticals, Inc. Composiciones farmaceuticas que comprenden peg-asparaginasa para el tratamiento de infecciones por vih.

Also Published As

Publication number Publication date
ZA200102506B (en) 2002-03-27
AU6894400A (en) 2001-03-05
CA2346063A1 (en) 2001-02-15
EP1143990A2 (de) 2001-10-17
WO2001010454B1 (en) 2002-07-11
HK1041444A1 (zh) 2002-07-12
WO2001010454A2 (en) 2001-02-15
JP2003506409A (ja) 2003-02-18
WO2001010454A3 (en) 2002-01-24
WO2001010454A9 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
AU3076700A (en) 2h-phthalazin-1-one derivatives and drugs comprising these derivatives as the active ingredient
AU2180400A (en) A pharmaceutical combination for the treatment of depression
PL351526A1 (en) Pharmaceutical formulation comprising amoxycillin
AU5259100A (en) Medicament
IL149663A0 (en) Devices for the delivery of drugs having antiprogestinic properties
AU4328800A (en) Pharmaceutical formulation
AU2002240359A1 (en) Pharmaceutical composition for the treatment of alopecia
AU2001269704A1 (en) Oxazinoquinolones useful for the treatment of viral infections
AU6715600A (en) Pharmaceutical formulations
AU1650401A (en) Oxadiazole derivatives and drugs containing these derivatives as the active ingredient
AU2281601A (en) Treatment of viral infections using levovirinTM
AU3669700A (en) 4-aminobutanoic acid derivatives and drugs containing these derivatives as the active ingredient
EP1143990A3 (de) Pharmazeutische zusammensetzung, enthaltend peg-asparaginase, für die behandlung von hiv infektionen
AU2002322082A1 (en) Pharmaceutical composition for the treatment of viral infection
AU4977300A (en) Pharmaceutical formulations
AU5842300A (en) Pharmaceutical composition useful for the treatment of tinnitus and hearing loss
AU1385801A (en) Pharmaceutical formulations
AU4145999A (en) Topical drug for the treatment of viral infections
AU1646201A (en) Pharmaceutical agent for the treatment of cachexia and/or cardiogenic shock
AU3839900A (en) Pharmaceutical formulation
AU1618901A (en) Treatment of rosacea
AU1388501A (en) Pharmaceutical formulation
AU4504201A (en) Drug preparations
AU7975500A (en) Drug for treatment of immunodeficiency states
AU1392601A (en) Prevention and treatment of biomaterial-associated infections

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

XX Miscellaneous

Free format text: DERZEIT SIND DIE WIPO-PUBLIKATIONSDATEN A3 NICHT VERFUEGBAR.

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17P Request for examination filed

Effective date: 20020709

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ENZON PHARMACEUTICALS, INC.

17Q First examination report despatched

Effective date: 20040407

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040818

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1041444

Country of ref document: HK